作者: Frederick B. Stehman
DOI: 10.5555/URI:PII:009377549290129O
关键词: Radiosensitizer 、 Medicine 、 Epithelioma 、 Placebo 、 Surgery 、 Adjuvant 、 Randomized controlled trial 、 Oncology 、 Internal medicine 、 Chemotherapy 、 Carcinoma 、 Cervix
摘要: Since 1968, hydroxyurea has been used as a radiosensitizer in combination modality treatments for carcinoma of the cervix. The drug shown an advantage over placebo several randomized trials. Although is given orally on outpatient basis, it not gained widespread acceptance. Previous reports are reviewed and possible future uses discussed.